Lupus Skin Drug Showed Promise in Phase 2 Trial
Adults with hard-to-treat skin lupus may see improvements with a new medication, according to recent study results.
Updated on Oct. 13, 2026 in Arthritis
Live Poll
Should patients with persistent skin inflammation seek specialist reassessment before waiting for current treatments to work?
Biogen reported 52-week data from the phase 2 AMETHYST study, which tested the drug litifilimab in 93 adults with active cutaneous lupus erythematosus. The findings suggest the treatment may help patients who have not responded to standard antimalarial therapies.
Why it matters
Uncontrolled cutaneous lupus can lead to permanent skin scarring and pigmentary changes, making new treatment options critical for long-term health. These results represent a potential new avenue for patients who have exhausted current conventional therapies.
In a phase 2 study of 93 adults with cutaneous lupus, 14.7% of litifilimab recipients reached clear or almost clear skin at week 16 compared to 2.9% of those on a placebo. Among those on active treatment, 27.2% achieved specific skin health scores at week 52.
The players
Biogen
A biotechnology company that focuses on developing therapies for neurological and immunological conditions including lupus.
The details
Litifilimab works by targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells, which are involved in the inflammatory processes of lupus. Patients who switched from placebo to the drug at week 24 showed skin improvement within four weeks. The study noted serious adverse events occurred in 6.8% of the treatment group during the initial 24 weeks and in 3.4% of participants during the extension period.
Timeline
March 2026: Biogen reported phase 2 trial data.
October 2, 2026: Biogen released AMETHYST 52-week data.
First half of 2027: Phase 3 results are expected.
Health Landscape
The AMETHYST phase 2 study provides early-stage clinical data for a novel therapeutic target in cutaneous lupus, extending research into plasmacytoid dendritic cell modulation. This trial follows the standard clinical development pathway for autoimmune skin therapies, moving from initial mechanism testing to long-term observation.
If you are living with cutaneous lupus that has not responded to antimalarial treatments, these preliminary results are worth discussing with your rheumatologist or dermatologist. While not yet an available treatment, understanding emerging options can help you prepare for future care conversations.
The takeaway
Early results suggest this new therapy could offer a potential solution for refractory skin lupus. Patients should monitor for upcoming phase 3 trial updates and continue tracking their skin changes with their specialist.
Further reading
Learn more about the latest research and standard care options in the Arthritis section.
More information
Review the detailed findings in the Biogen phase 2 study results.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should patients with persistent skin inflammation seek specialist reassessment before waiting for current treatments to work?
